BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35331811)

  • 1. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
    Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
    Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities.
    Kolin DL; Quick CM; Dong F; Fletcher CDM; Stewart CJR; Soma A; Hornick JL; Nucci MR; Howitt BE
    Am J Surg Pathol; 2020 Feb; 44(2):263-270. PubMed ID: 31567195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.
    Kommoss FK; Tessier-Cloutier B; Witkowski L; Forgo E; Koelsche C; Köbel M; Foulkes WD; Lee CH; Kolin DL; von Deimling A; Howitt BE
    J Pathol; 2022 Jun; 257(2):140-145. PubMed ID: 35218556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
    Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
    Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma.
    Gao J; Fan R; Chen D; Hou J; Chen H; Lu M
    Diagn Pathol; 2023 May; 18(1):62. PubMed ID: 37194064
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Nakra T; Kakkar A; Mathur SR; Jain D; Kumar S
    Int J Surg Pathol; 2023 Feb; 31(1):104-109. PubMed ID: 35466749
    [No Abstract]   [Full Text] [Related]  

  • 7. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution.
    Korentzelos D; Elishaev E; Zhao C; Jones MW; Soong TR; Lesnock J; Orellana T; Zeccola A; Diamantopoulos LN; Wald AI; Bhargava R
    Hum Pathol; 2022 Dec; 130():65-78. PubMed ID: 36252860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
    Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
    Kolin DL; Dong F; Baltay M; Lindeman N; MacConaill L; Nucci MR; Crum CP; Howitt BE
    Mod Pathol; 2018 Sep; 31(9):1442-1456. PubMed ID: 29700418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
    Nambirajan A; Jain D
    Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
    Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A
    Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
    Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
    Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
    Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
    J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.
    Lin DI; Allen JM; Hecht JL; Killian JK; Ngo NT; Edgerly C; Severson EA; Ali SM; Erlich RL; Ramkissoon SH; Vergilio JA; Ross JS; Elvin JA
    Mod Pathol; 2019 Nov; 32(11):1675-1687. PubMed ID: 31190001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
    Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
    Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
    Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
    Hum Pathol; 2021 Oct; 116():12-21. PubMed ID: 34271067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression.
    Tessier-Cloutier B; Kang EY; Alex D; Stewart CJR; McCluggage WG; Köbel M; Lee CH
    Histopathology; 2022 Jul; 81(1):44-54. PubMed ID: 35394077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
    Ramalingam P; Croce S; McCluggage WG
    Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.